骨科

订阅

MedSci主页 / 所有栏目 / 骨科

Biochem Biophys Res Commun：甲状旁腺激素（PTH）通过调节SIK2和Wnt4促进ADSC成骨

2019-06-30 不详 网络

关注

开发骨再生方法和揭示骨形成的分子机制对人类健康具有重要意义。在过去的十年中，人们一直在使用能够进行多向分化的脂肪来源的干细胞（ADSCs）来重建缺陷的骨骼。揭示ADSCs成骨细胞分化的分子机制将提供对ADSCs在骨再生应用中的更多理解，并可能是骨质疏松症治疗的新方法。在这里，我们研究了甲状旁腺激素（PTH1-34）如何作用于骨诱导的ADSCs以协调骨形成，以及Wnt4信号传导如何参与ADSCs促进

开发骨再生方法和揭示骨形成的分子机制对人类健康具有重要意义。在过去的十年中，人们一直在使用能够进行多向分化的脂肪来源的干细胞（ADSCs）来重建缺陷的骨骼。揭示ADSCs成骨细胞分化的分子机制将提供对ADSCs在骨再生应用中的更多理解，并可能是骨质疏松症治疗的新方法。在这里，我们研究了甲状旁腺激素（PTH1-34）如何作用于骨诱导的ADSCs以协调骨形成，以及Wnt4信号传导如何参与ADSCs促进PTH促进的骨形成。

结果发现，PTH1-34可以磷酸化SIK2，上调RANKL并下调SOST，从而上调Wnt4以促进ADSC的成骨过程。虽然具有shRNA干扰的Wnt4的敲低几乎不影响上游蛋白的表达，但它影响其他下游成骨蛋白的表达，然后抑制ADSC的成骨过程。

总之，PTH可通过调节SIK2和Wnt4来影响ADSC的成骨过程。我们预计这项工作将为研究人员提供ADSC骨再生的新见解。

原始出处：

An Y, Zhao J, et al., Parathyroid hormone (PTH) promotes ADSC osteogenesis by regulating SIK2 and Wnt4. Biochem Biophys Res Commun. 2019 Jun 21. pii: S0006-291X(19)31222-7. doi: 10.1016/j.bbrc.2019.06.084.

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1707576, encodeId=5ae11e0757676, content=<a href='/topic/show?id=9f7c99e256' target=_blank style='color:#2F92EE;'>#IOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9972, encryptionId=9f7c99e256, topicName=IOP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb031431834, createdName=124987c6m46暂无昵称, createdTime=Fri Jul 12 14:43:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024128, encodeId=a7db202412894, content=<a href='/topic/show?id=2d551484e95' target=_blank style='color:#2F92EE;'>#PTH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14847, encryptionId=2d551484e95, topicName=PTH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c5e117, createdName=lujian, createdTime=Sun Mar 01 12:43:00 CST 2020, time=2020-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918762, encodeId=02691918e62f2, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Apr 19 23:43:00 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087555, encodeId=ddc6208e5555e, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Sep 07 05:43:00 CST 2019, time=2019-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794089, encodeId=c8ef1e940894a, content=<a href='/topic/show?id=1f73163127a' target=_blank style='color:#2F92EE;'>#SIK2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16312, encryptionId=1f73163127a, topicName=SIK2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Wed Jul 03 07:43:00 CST 2019, time=2019-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029520, encodeId=3945202952040, content=<a href='/topic/show?id=c4222014ff' target=_blank style='color:#2F92EE;'>#ADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2014, encryptionId=c4222014ff, topicName=ADS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Fri Apr 17 19:43:00 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352186, encodeId=654e135218602, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jul 02 14:43:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452473, encodeId=cdff14524e382, content=<a href='/topic/show?id=d90469826e2' target=_blank style='color:#2F92EE;'>#甲状旁腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69826, encryptionId=d90469826e2, topicName=甲状旁腺)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=84ba5566863, createdName=huperzia, createdTime=Tue Jul 02 14:43:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598659, encodeId=2b611598659c7, content=<a href='/topic/show?id=c4da18e2588' target=_blank style='color:#2F92EE;'>#WNT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18725, encryptionId=c4da18e2588, topicName=WNT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb3518632538, createdName=zhwj, createdTime=Tue Jul 02 14:43:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798692, encodeId=1f621e9869222, content=<a href='/topic/show?id=964669838ac' target=_blank style='color:#2F92EE;'>#甲状旁腺激素（PTH）#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69838, encryptionId=964669838ac, topicName=甲状旁腺激素（PTH）)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e72268, createdName=zhixianchen, createdTime=Tue Sep 03 20:43:00 CST 2019, time=2019-09-03, status=1, ipAttribution=)]
    2019-07-12 124987c6m46暂无昵称

    #IOP#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1707576, encodeId=5ae11e0757676, content=<a href='/topic/show?id=9f7c99e256' target=_blank style='color:#2F92EE;'>#IOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9972, encryptionId=9f7c99e256, topicName=IOP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb031431834, createdName=124987c6m46暂无昵称, createdTime=Fri Jul 12 14:43:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024128, encodeId=a7db202412894, content=<a href='/topic/show?id=2d551484e95' target=_blank style='color:#2F92EE;'>#PTH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14847, encryptionId=2d551484e95, topicName=PTH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c5e117, createdName=lujian, createdTime=Sun Mar 01 12:43:00 CST 2020, time=2020-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918762, encodeId=02691918e62f2, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Apr 19 23:43:00 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087555, encodeId=ddc6208e5555e, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Sep 07 05:43:00 CST 2019, time=2019-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794089, encodeId=c8ef1e940894a, content=<a href='/topic/show?id=1f73163127a' target=_blank style='color:#2F92EE;'>#SIK2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16312, encryptionId=1f73163127a, topicName=SIK2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Wed Jul 03 07:43:00 CST 2019, time=2019-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029520, encodeId=3945202952040, content=<a href='/topic/show?id=c4222014ff' target=_blank style='color:#2F92EE;'>#ADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2014, encryptionId=c4222014ff, topicName=ADS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Fri Apr 17 19:43:00 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352186, encodeId=654e135218602, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jul 02 14:43:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452473, encodeId=cdff14524e382, content=<a href='/topic/show?id=d90469826e2' target=_blank style='color:#2F92EE;'>#甲状旁腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69826, encryptionId=d90469826e2, topicName=甲状旁腺)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=84ba5566863, createdName=huperzia, createdTime=Tue Jul 02 14:43:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598659, encodeId=2b611598659c7, content=<a href='/topic/show?id=c4da18e2588' target=_blank style='color:#2F92EE;'>#WNT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18725, encryptionId=c4da18e2588, topicName=WNT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb3518632538, createdName=zhwj, createdTime=Tue Jul 02 14:43:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798692, encodeId=1f621e9869222, content=<a href='/topic/show?id=964669838ac' target=_blank style='color:#2F92EE;'>#甲状旁腺激素（PTH）#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69838, encryptionId=964669838ac, topicName=甲状旁腺激素（PTH）)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e72268, createdName=zhixianchen, createdTime=Tue Sep 03 20:43:00 CST 2019, time=2019-09-03, status=1, ipAttribution=)]
    2020-03-01 lujian

    #PTH#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1707576, encodeId=5ae11e0757676, content=<a href='/topic/show?id=9f7c99e256' target=_blank style='color:#2F92EE;'>#IOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9972, encryptionId=9f7c99e256, topicName=IOP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb031431834, createdName=124987c6m46暂无昵称, createdTime=Fri Jul 12 14:43:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024128, encodeId=a7db202412894, content=<a href='/topic/show?id=2d551484e95' target=_blank style='color:#2F92EE;'>#PTH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14847, encryptionId=2d551484e95, topicName=PTH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c5e117, createdName=lujian, createdTime=Sun Mar 01 12:43:00 CST 2020, time=2020-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918762, encodeId=02691918e62f2, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Apr 19 23:43:00 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087555, encodeId=ddc6208e5555e, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Sep 07 05:43:00 CST 2019, time=2019-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794089, encodeId=c8ef1e940894a, content=<a href='/topic/show?id=1f73163127a' target=_blank style='color:#2F92EE;'>#SIK2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16312, encryptionId=1f73163127a, topicName=SIK2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Wed Jul 03 07:43:00 CST 2019, time=2019-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029520, encodeId=3945202952040, content=<a href='/topic/show?id=c4222014ff' target=_blank style='color:#2F92EE;'>#ADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2014, encryptionId=c4222014ff, topicName=ADS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Fri Apr 17 19:43:00 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352186, encodeId=654e135218602, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jul 02 14:43:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452473, encodeId=cdff14524e382, content=<a href='/topic/show?id=d90469826e2' target=_blank style='color:#2F92EE;'>#甲状旁腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69826, encryptionId=d90469826e2, topicName=甲状旁腺)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=84ba5566863, createdName=huperzia, createdTime=Tue Jul 02 14:43:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598659, encodeId=2b611598659c7, content=<a href='/topic/show?id=c4da18e2588' target=_blank style='color:#2F92EE;'>#WNT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18725, encryptionId=c4da18e2588, topicName=WNT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb3518632538, createdName=zhwj, createdTime=Tue Jul 02 14:43:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798692, encodeId=1f621e9869222, content=<a href='/topic/show?id=964669838ac' target=_blank style='color:#2F92EE;'>#甲状旁腺激素（PTH）#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69838, encryptionId=964669838ac, topicName=甲状旁腺激素（PTH）)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e72268, createdName=zhixianchen, createdTime=Tue Sep 03 20:43:00 CST 2019, time=2019-09-03, status=1, ipAttribution=)]
    2020-04-19 sunylz

    #Bio#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1707576, encodeId=5ae11e0757676, content=<a href='/topic/show?id=9f7c99e256' target=_blank style='color:#2F92EE;'>#IOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9972, encryptionId=9f7c99e256, topicName=IOP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb031431834, createdName=124987c6m46暂无昵称, createdTime=Fri Jul 12 14:43:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024128, encodeId=a7db202412894, content=<a href='/topic/show?id=2d551484e95' target=_blank style='color:#2F92EE;'>#PTH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14847, encryptionId=2d551484e95, topicName=PTH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c5e117, createdName=lujian, createdTime=Sun Mar 01 12:43:00 CST 2020, time=2020-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918762, encodeId=02691918e62f2, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Apr 19 23:43:00 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087555, encodeId=ddc6208e5555e, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Sep 07 05:43:00 CST 2019, time=2019-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794089, encodeId=c8ef1e940894a, content=<a href='/topic/show?id=1f73163127a' target=_blank style='color:#2F92EE;'>#SIK2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16312, encryptionId=1f73163127a, topicName=SIK2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Wed Jul 03 07:43:00 CST 2019, time=2019-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029520, encodeId=3945202952040, content=<a href='/topic/show?id=c4222014ff' target=_blank style='color:#2F92EE;'>#ADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2014, encryptionId=c4222014ff, topicName=ADS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Fri Apr 17 19:43:00 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352186, encodeId=654e135218602, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jul 02 14:43:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452473, encodeId=cdff14524e382, content=<a href='/topic/show?id=d90469826e2' target=_blank style='color:#2F92EE;'>#甲状旁腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69826, encryptionId=d90469826e2, topicName=甲状旁腺)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=84ba5566863, createdName=huperzia, createdTime=Tue Jul 02 14:43:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598659, encodeId=2b611598659c7, content=<a href='/topic/show?id=c4da18e2588' target=_blank style='color:#2F92EE;'>#WNT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18725, encryptionId=c4da18e2588, topicName=WNT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb3518632538, createdName=zhwj, createdTime=Tue Jul 02 14:43:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798692, encodeId=1f621e9869222, content=<a href='/topic/show?id=964669838ac' target=_blank style='color:#2F92EE;'>#甲状旁腺激素（PTH）#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69838, encryptionId=964669838ac, topicName=甲状旁腺激素（PTH）)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e72268, createdName=zhixianchen, createdTime=Tue Sep 03 20:43:00 CST 2019, time=2019-09-03, status=1, ipAttribution=)]
    2019-09-07 liuli5079

    #COMMUN#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1707576, encodeId=5ae11e0757676, content=<a href='/topic/show?id=9f7c99e256' target=_blank style='color:#2F92EE;'>#IOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9972, encryptionId=9f7c99e256, topicName=IOP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb031431834, createdName=124987c6m46暂无昵称, createdTime=Fri Jul 12 14:43:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024128, encodeId=a7db202412894, content=<a href='/topic/show?id=2d551484e95' target=_blank style='color:#2F92EE;'>#PTH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14847, encryptionId=2d551484e95, topicName=PTH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c5e117, createdName=lujian, createdTime=Sun Mar 01 12:43:00 CST 2020, time=2020-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918762, encodeId=02691918e62f2, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Apr 19 23:43:00 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087555, encodeId=ddc6208e5555e, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Sep 07 05:43:00 CST 2019, time=2019-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794089, encodeId=c8ef1e940894a, content=<a href='/topic/show?id=1f73163127a' target=_blank style='color:#2F92EE;'>#SIK2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16312, encryptionId=1f73163127a, topicName=SIK2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Wed Jul 03 07:43:00 CST 2019, time=2019-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029520, encodeId=3945202952040, content=<a href='/topic/show?id=c4222014ff' target=_blank style='color:#2F92EE;'>#ADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2014, encryptionId=c4222014ff, topicName=ADS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Fri Apr 17 19:43:00 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352186, encodeId=654e135218602, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jul 02 14:43:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452473, encodeId=cdff14524e382, content=<a href='/topic/show?id=d90469826e2' target=_blank style='color:#2F92EE;'>#甲状旁腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69826, encryptionId=d90469826e2, topicName=甲状旁腺)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=84ba5566863, createdName=huperzia, createdTime=Tue Jul 02 14:43:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598659, encodeId=2b611598659c7, content=<a href='/topic/show?id=c4da18e2588' target=_blank style='color:#2F92EE;'>#WNT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18725, encryptionId=c4da18e2588, topicName=WNT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb3518632538, createdName=zhwj, createdTime=Tue Jul 02 14:43:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798692, encodeId=1f621e9869222, content=<a href='/topic/show?id=964669838ac' target=_blank style='color:#2F92EE;'>#甲状旁腺激素（PTH）#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69838, encryptionId=964669838ac, topicName=甲状旁腺激素（PTH）)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e72268, createdName=zhixianchen, createdTime=Tue Sep 03 20:43:00 CST 2019, time=2019-09-03, status=1, ipAttribution=)]
    2019-07-03 oliver169

    #SIK2#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1707576, encodeId=5ae11e0757676, content=<a href='/topic/show?id=9f7c99e256' target=_blank style='color:#2F92EE;'>#IOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9972, encryptionId=9f7c99e256, topicName=IOP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb031431834, createdName=124987c6m46暂无昵称, createdTime=Fri Jul 12 14:43:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024128, encodeId=a7db202412894, content=<a href='/topic/show?id=2d551484e95' target=_blank style='color:#2F92EE;'>#PTH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14847, encryptionId=2d551484e95, topicName=PTH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c5e117, createdName=lujian, createdTime=Sun Mar 01 12:43:00 CST 2020, time=2020-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918762, encodeId=02691918e62f2, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Apr 19 23:43:00 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087555, encodeId=ddc6208e5555e, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Sep 07 05:43:00 CST 2019, time=2019-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794089, encodeId=c8ef1e940894a, content=<a href='/topic/show?id=1f73163127a' target=_blank style='color:#2F92EE;'>#SIK2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16312, encryptionId=1f73163127a, topicName=SIK2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Wed Jul 03 07:43:00 CST 2019, time=2019-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029520, encodeId=3945202952040, content=<a href='/topic/show?id=c4222014ff' target=_blank style='color:#2F92EE;'>#ADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2014, encryptionId=c4222014ff, topicName=ADS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Fri Apr 17 19:43:00 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352186, encodeId=654e135218602, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jul 02 14:43:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452473, encodeId=cdff14524e382, content=<a href='/topic/show?id=d90469826e2' target=_blank style='color:#2F92EE;'>#甲状旁腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69826, encryptionId=d90469826e2, topicName=甲状旁腺)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=84ba5566863, createdName=huperzia, createdTime=Tue Jul 02 14:43:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598659, encodeId=2b611598659c7, content=<a href='/topic/show?id=c4da18e2588' target=_blank style='color:#2F92EE;'>#WNT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18725, encryptionId=c4da18e2588, topicName=WNT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb3518632538, createdName=zhwj, createdTime=Tue Jul 02 14:43:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798692, encodeId=1f621e9869222, content=<a href='/topic/show?id=964669838ac' target=_blank style='color:#2F92EE;'>#甲状旁腺激素（PTH）#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69838, encryptionId=964669838ac, topicName=甲状旁腺激素（PTH）)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e72268, createdName=zhixianchen, createdTime=Tue Sep 03 20:43:00 CST 2019, time=2019-09-03, status=1, ipAttribution=)]
    2020-04-17 1249898am15暂无昵称

    #ADS#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1707576, encodeId=5ae11e0757676, content=<a href='/topic/show?id=9f7c99e256' target=_blank style='color:#2F92EE;'>#IOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9972, encryptionId=9f7c99e256, topicName=IOP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb031431834, createdName=124987c6m46暂无昵称, createdTime=Fri Jul 12 14:43:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024128, encodeId=a7db202412894, content=<a href='/topic/show?id=2d551484e95' target=_blank style='color:#2F92EE;'>#PTH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14847, encryptionId=2d551484e95, topicName=PTH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c5e117, createdName=lujian, createdTime=Sun Mar 01 12:43:00 CST 2020, time=2020-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918762, encodeId=02691918e62f2, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Apr 19 23:43:00 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087555, encodeId=ddc6208e5555e, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Sep 07 05:43:00 CST 2019, time=2019-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794089, encodeId=c8ef1e940894a, content=<a href='/topic/show?id=1f73163127a' target=_blank style='color:#2F92EE;'>#SIK2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16312, encryptionId=1f73163127a, topicName=SIK2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Wed Jul 03 07:43:00 CST 2019, time=2019-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029520, encodeId=3945202952040, content=<a href='/topic/show?id=c4222014ff' target=_blank style='color:#2F92EE;'>#ADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2014, encryptionId=c4222014ff, topicName=ADS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Fri Apr 17 19:43:00 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352186, encodeId=654e135218602, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jul 02 14:43:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452473, encodeId=cdff14524e382, content=<a href='/topic/show?id=d90469826e2' target=_blank style='color:#2F92EE;'>#甲状旁腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69826, encryptionId=d90469826e2, topicName=甲状旁腺)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=84ba5566863, createdName=huperzia, createdTime=Tue Jul 02 14:43:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598659, encodeId=2b611598659c7, content=<a href='/topic/show?id=c4da18e2588' target=_blank style='color:#2F92EE;'>#WNT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18725, encryptionId=c4da18e2588, topicName=WNT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb3518632538, createdName=zhwj, createdTime=Tue Jul 02 14:43:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798692, encodeId=1f621e9869222, content=<a href='/topic/show?id=964669838ac' target=_blank style='color:#2F92EE;'>#甲状旁腺激素（PTH）#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69838, encryptionId=964669838ac, topicName=甲状旁腺激素（PTH）)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e72268, createdName=zhixianchen, createdTime=Tue Sep 03 20:43:00 CST 2019, time=2019-09-03, status=1, ipAttribution=)]
    2019-07-02 zhaojie88

    #成骨#

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1707576, encodeId=5ae11e0757676, content=<a href='/topic/show?id=9f7c99e256' target=_blank style='color:#2F92EE;'>#IOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9972, encryptionId=9f7c99e256, topicName=IOP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb031431834, createdName=124987c6m46暂无昵称, createdTime=Fri Jul 12 14:43:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024128, encodeId=a7db202412894, content=<a href='/topic/show?id=2d551484e95' target=_blank style='color:#2F92EE;'>#PTH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14847, encryptionId=2d551484e95, topicName=PTH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c5e117, createdName=lujian, createdTime=Sun Mar 01 12:43:00 CST 2020, time=2020-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918762, encodeId=02691918e62f2, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Apr 19 23:43:00 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087555, encodeId=ddc6208e5555e, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Sep 07 05:43:00 CST 2019, time=2019-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794089, encodeId=c8ef1e940894a, content=<a href='/topic/show?id=1f73163127a' target=_blank style='color:#2F92EE;'>#SIK2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16312, encryptionId=1f73163127a, topicName=SIK2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Wed Jul 03 07:43:00 CST 2019, time=2019-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029520, encodeId=3945202952040, content=<a href='/topic/show?id=c4222014ff' target=_blank style='color:#2F92EE;'>#ADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2014, encryptionId=c4222014ff, topicName=ADS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Fri Apr 17 19:43:00 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352186, encodeId=654e135218602, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jul 02 14:43:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452473, encodeId=cdff14524e382, content=<a href='/topic/show?id=d90469826e2' target=_blank style='color:#2F92EE;'>#甲状旁腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69826, encryptionId=d90469826e2, topicName=甲状旁腺)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=84ba5566863, createdName=huperzia, createdTime=Tue Jul 02 14:43:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598659, encodeId=2b611598659c7, content=<a href='/topic/show?id=c4da18e2588' target=_blank style='color:#2F92EE;'>#WNT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18725, encryptionId=c4da18e2588, topicName=WNT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb3518632538, createdName=zhwj, createdTime=Tue Jul 02 14:43:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798692, encodeId=1f621e9869222, content=<a href='/topic/show?id=964669838ac' target=_blank style='color:#2F92EE;'>#甲状旁腺激素（PTH）#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69838, encryptionId=964669838ac, topicName=甲状旁腺激素（PTH）)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e72268, createdName=zhixianchen, createdTime=Tue Sep 03 20:43:00 CST 2019, time=2019-09-03, status=1, ipAttribution=)]
    2019-07-02 huperzia

    #甲状旁腺#

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1707576, encodeId=5ae11e0757676, content=<a href='/topic/show?id=9f7c99e256' target=_blank style='color:#2F92EE;'>#IOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9972, encryptionId=9f7c99e256, topicName=IOP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb031431834, createdName=124987c6m46暂无昵称, createdTime=Fri Jul 12 14:43:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024128, encodeId=a7db202412894, content=<a href='/topic/show?id=2d551484e95' target=_blank style='color:#2F92EE;'>#PTH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14847, encryptionId=2d551484e95, topicName=PTH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c5e117, createdName=lujian, createdTime=Sun Mar 01 12:43:00 CST 2020, time=2020-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918762, encodeId=02691918e62f2, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Apr 19 23:43:00 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087555, encodeId=ddc6208e5555e, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Sep 07 05:43:00 CST 2019, time=2019-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794089, encodeId=c8ef1e940894a, content=<a href='/topic/show?id=1f73163127a' target=_blank style='color:#2F92EE;'>#SIK2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16312, encryptionId=1f73163127a, topicName=SIK2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Wed Jul 03 07:43:00 CST 2019, time=2019-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029520, encodeId=3945202952040, content=<a href='/topic/show?id=c4222014ff' target=_blank style='color:#2F92EE;'>#ADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2014, encryptionId=c4222014ff, topicName=ADS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Fri Apr 17 19:43:00 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352186, encodeId=654e135218602, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jul 02 14:43:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452473, encodeId=cdff14524e382, content=<a href='/topic/show?id=d90469826e2' target=_blank style='color:#2F92EE;'>#甲状旁腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69826, encryptionId=d90469826e2, topicName=甲状旁腺)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=84ba5566863, createdName=huperzia, createdTime=Tue Jul 02 14:43:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598659, encodeId=2b611598659c7, content=<a href='/topic/show?id=c4da18e2588' target=_blank style='color:#2F92EE;'>#WNT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18725, encryptionId=c4da18e2588, topicName=WNT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb3518632538, createdName=zhwj, createdTime=Tue Jul 02 14:43:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798692, encodeId=1f621e9869222, content=<a href='/topic/show?id=964669838ac' target=_blank style='color:#2F92EE;'>#甲状旁腺激素（PTH）#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69838, encryptionId=964669838ac, topicName=甲状旁腺激素（PTH）)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e72268, createdName=zhixianchen, createdTime=Tue Sep 03 20:43:00 CST 2019, time=2019-09-03, status=1, ipAttribution=)]
    2019-07-02 zhwj

    #WNT#

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1707576, encodeId=5ae11e0757676, content=<a href='/topic/show?id=9f7c99e256' target=_blank style='color:#2F92EE;'>#IOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9972, encryptionId=9f7c99e256, topicName=IOP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb031431834, createdName=124987c6m46暂无昵称, createdTime=Fri Jul 12 14:43:00 CST 2019, time=2019-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024128, encodeId=a7db202412894, content=<a href='/topic/show?id=2d551484e95' target=_blank style='color:#2F92EE;'>#PTH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14847, encryptionId=2d551484e95, topicName=PTH)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c5e117, createdName=lujian, createdTime=Sun Mar 01 12:43:00 CST 2020, time=2020-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918762, encodeId=02691918e62f2, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Apr 19 23:43:00 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087555, encodeId=ddc6208e5555e, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7931272, createdName=liuli5079, createdTime=Sat Sep 07 05:43:00 CST 2019, time=2019-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1794089, encodeId=c8ef1e940894a, content=<a href='/topic/show?id=1f73163127a' target=_blank style='color:#2F92EE;'>#SIK2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16312, encryptionId=1f73163127a, topicName=SIK2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4fd6156, createdName=oliver169, createdTime=Wed Jul 03 07:43:00 CST 2019, time=2019-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029520, encodeId=3945202952040, content=<a href='/topic/show?id=c4222014ff' target=_blank style='color:#2F92EE;'>#ADS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2014, encryptionId=c4222014ff, topicName=ADS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=38232500109, createdName=1249898am15暂无昵称, createdTime=Fri Apr 17 19:43:00 CST 2020, time=2020-04-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352186, encodeId=654e135218602, content=<a href='/topic/show?id=e95954093cd' target=_blank style='color:#2F92EE;'>#成骨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54093, encryptionId=e95954093cd, topicName=成骨)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Jul 02 14:43:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452473, encodeId=cdff14524e382, content=<a href='/topic/show?id=d90469826e2' target=_blank style='color:#2F92EE;'>#甲状旁腺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69826, encryptionId=d90469826e2, topicName=甲状旁腺)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=84ba5566863, createdName=huperzia, createdTime=Tue Jul 02 14:43:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598659, encodeId=2b611598659c7, content=<a href='/topic/show?id=c4da18e2588' target=_blank style='color:#2F92EE;'>#WNT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18725, encryptionId=c4da18e2588, topicName=WNT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eb3518632538, createdName=zhwj, createdTime=Tue Jul 02 14:43:00 CST 2019, time=2019-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798692, encodeId=1f621e9869222, content=<a href='/topic/show?id=964669838ac' target=_blank style='color:#2F92EE;'>#甲状旁腺激素（PTH）#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69838, encryptionId=964669838ac, topicName=甲状旁腺激素（PTH）)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e72268, createdName=zhixianchen, createdTime=Tue Sep 03 20:43:00 CST 2019, time=2019-09-03, status=1, ipAttribution=)]
    2019-09-03 zhixianchen

    #甲状旁腺激素（PTH）#

    0

以上为热门评论，梅斯医学App还有更多内容